Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have been given a consensus rating of “Buy” by the nine brokerages that are presently covering the company. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $38.38.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Thursday. HC Wainwright upped their price target on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Robert W. Baird reiterated an “outperform” rating and set a $40.00 price objective on shares of Paratek Pharmaceuticals in a research note on Tuesday, April 4th. BTIG Research boosted their price objective on shares of Paratek Pharmaceuticals from $47.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, April 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $32.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, March 30th.
In other Paratek Pharmaceuticals news, CFO Douglas W. Pagan sold 3,405 shares of the stock in a transaction on Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $51,381.45. Following the transaction, the chief financial officer now directly owns 58,983 shares of the company’s stock, valued at $890,053.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Evan Loh sold 3,106 shares of the stock in a transaction on Monday, February 6th. The shares were sold at an average price of $15.09, for a total transaction of $46,869.54. Following the transaction, the chief operating officer now directly owns 102,873 shares in the company, valued at $1,552,353.57. The disclosure for this sale can be found here. Insiders have sold 11,511 shares of company stock worth $173,701 over the last three months. 2.00% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of PRTK. Wells Fargo & Company MN boosted its stake in shares of Paratek Pharmaceuticals by 196.5% in the third quarter. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company’s stock worth $104,000 after buying an additional 5,305 shares during the period. Ardsley Advisory Partners acquired a new stake in shares of Paratek Pharmaceuticals during the third quarter worth approximately $130,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Paratek Pharmaceuticals during the fourth quarter worth approximately $158,000. Ellington Management Group LLC acquired a new stake in shares of Paratek Pharmaceuticals during the fourth quarter worth approximately $179,000. Finally, Croft Leominster Inc. acquired a new stake in shares of Paratek Pharmaceuticals during the third quarter worth approximately $188,000. Institutional investors and hedge funds own 76.06% of the company’s stock.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down 0.23% on Tuesday, reaching $21.55. The company had a trading volume of 468,939 shares. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $25.00. The company’s 50-day moving average is $18.64 and its 200-day moving average is $15.06. The company’s market capitalization is $523.36 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Thursday, March 2nd. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.17. The business earned $0.03 million during the quarter.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).
Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.